JP2020521447A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521447A5
JP2020521447A5 JP2019564782A JP2019564782A JP2020521447A5 JP 2020521447 A5 JP2020521447 A5 JP 2020521447A5 JP 2019564782 A JP2019564782 A JP 2019564782A JP 2019564782 A JP2019564782 A JP 2019564782A JP 2020521447 A5 JP2020521447 A5 JP 2020521447A5
Authority
JP
Japan
Prior art keywords
drawings
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019564782A
Other languages
English (en)
Japanese (ja)
Other versions
JP7522426B2 (ja
JP2020521447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/034655 external-priority patent/WO2018218151A1/en
Publication of JP2020521447A publication Critical patent/JP2020521447A/ja
Publication of JP2020521447A5 publication Critical patent/JP2020521447A5/ja
Priority to JP2024109160A priority Critical patent/JP2024133640A/ja
Application granted granted Critical
Publication of JP7522426B2 publication Critical patent/JP7522426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019564782A 2017-05-25 2018-05-25 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス Active JP7522426B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024109160A JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511010P 2017-05-25 2017-05-25
US62/511,010 2017-05-25
PCT/US2018/034655 WO2018218151A1 (en) 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024109160A Division JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Publications (3)

Publication Number Publication Date
JP2020521447A JP2020521447A (ja) 2020-07-27
JP2020521447A5 true JP2020521447A5 (enExample) 2021-07-26
JP7522426B2 JP7522426B2 (ja) 2024-07-25

Family

ID=64397136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019564782A Active JP7522426B2 (ja) 2017-05-25 2018-05-25 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス
JP2024109160A Pending JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024109160A Pending JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Country Status (10)

Country Link
US (2) US11684637B2 (enExample)
EP (1) EP3630144A4 (enExample)
JP (2) JP7522426B2 (enExample)
KR (2) KR102700175B1 (enExample)
CN (1) CN110891584B (enExample)
AU (1) AU2018273963B2 (enExample)
BR (1) BR112019024656A2 (enExample)
CA (1) CA3064897A1 (enExample)
IL (1) IL270876B2 (enExample)
WO (1) WO2018218151A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
AU2020211456A1 (en) * 2019-01-24 2021-08-26 University Of Central Florida Research Foundation, Inc. Compositions and methods for stimulating natural killer cells
KR20220151601A (ko) * 2019-11-25 2022-11-15 안선 바이오파르마, 아이엔씨. 암세포, 면역세포 및 종양 미세환경으로의 시알리다제의 면역세포 전달
CN111676245B (zh) * 2020-06-24 2022-09-13 武汉波睿达生物科技有限公司 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
US20240191252A1 (en) * 2021-04-08 2024-06-13 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN116875547A (zh) * 2023-09-04 2023-10-13 山东德升细胞治疗工程技术有限公司 一种利用细胞外泌体激活nk细胞的体外扩增培养方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
WO2002080983A1 (en) * 2001-04-05 2002-10-17 The Uab Research Foundation Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
JP2009513608A (ja) 2005-10-28 2009-04-02 ノボ・ノルデイスク・エー/エス エフェクターリンパ球と標的細胞とを結合する融合タンパク質
WO2008067305A2 (en) 2006-11-28 2008-06-05 Giic Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
FR2938840B1 (fr) * 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
SI2379586T1 (sl) 2008-12-22 2017-02-28 Targovax Oy Onkolitični adenovirusni vektorji in z njimi povezani postopki in uporabe
WO2011044158A1 (en) * 2009-10-09 2011-04-14 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CN108130345A (zh) 2012-01-24 2018-06-08 乔治亚大学研究基金公司 基于副流感病毒5的疫苗
PT3578201T (pt) * 2012-06-28 2023-05-10 Univ Of Central Florida Research Foundation Incorporated Métodos e composições para células assassinas naturais
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014041119A1 (en) * 2012-09-14 2014-03-20 Deutsches Krebsforschungszentrum Oncolytic viruses expressing immuno-nucleases
WO2014158811A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
US20170007685A1 (en) 2013-11-05 2017-01-12 The Board Of Regents Of The University Of Texas System TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
US10238700B2 (en) * 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10512684B2 (en) * 2014-09-26 2019-12-24 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
BR112017008696A2 (pt) 2014-10-27 2017-12-26 Univ Central Florida Res Found Inc métodos e composições para células exterminadoras naturais
WO2016109668A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
PT3280729T (pt) * 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes

Similar Documents

Publication Publication Date Title
JP2020530297A5 (enExample)
JP2019030304A5 (enExample)
JP2019099571A5 (enExample)
JP2022028828A5 (enExample)
JP2021502066A5 (enExample)
JP2022025124A5 (enExample)
JP2020042034A5 (enExample)
JP2021185136A5 (enExample)
JP2021169491A5 (enExample)
JP2018154848A5 (enExample)
JP2021500894A5 (enExample)
JP2020040981A5 (enExample)
JP2021503478A5 (enExample)
JP2020534795A5 (enExample)
JP2020127428A5 (enExample)
JP2020007340A5 (enExample)
JP2021028398A5 (enExample)
JP2021038271A5 (enExample)
JP2019031552A5 (enExample)
JP2019068846A5 (enExample)
JP2019536002A5 (enExample)
JP2017214405A5 (enExample)
JP2016196495A5 (enExample)
JP2020010717A5 (enExample)
JPWO2020148954A5 (enExample)